S
Sorachai Nitayaphan
Researcher at United States Department of the Army
Publications - 133
Citations - 11905
Sorachai Nitayaphan is an academic researcher from United States Department of the Army. The author has contributed to research in topics: Antibody & Vaccine trial. The author has an hindex of 41, co-authored 124 publications receiving 10982 citations.
Papers
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes,Peter B. Gilbert,M. Juliana McElrath,Susan Zolla-Pazner,Georgia D. Tomaras,S. Munir Alam,David T. Evans,David C. Montefiori,Chitraporn Karnasuta,Ruengpueng Sutthent,Hua-Xin Liao,Anthony L. DeVico,George K. Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan C. deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin L. Robb,Viseth Ngauy,Mark de Souza,Robert Paris,Guido Ferrari,Robert T. Bailer,Kelly A. Soderberg,Charla Andrews,Phillip W. Berman,Nicole Frahm,Stephen C. De Rosa,Michael D. Alpert,Nicole L. Yates,Xiaoying Shen,Richard A. Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Nelson L. Michael,Jerome H. Kim +42 more
TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Journal ArticleDOI
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland,Paul T. Edlefsen,Brendan B. Larsen,Sodsai Tovanabutra,Eric Sanders-Buell,Tomer Hertz,Allan C. deCamp,Chris Carrico,Chris Carrico,Sergey Menis,Sergey Menis,Craig A. Magaret,Hasan Ahmed,Michal Juraska,Lennie Chen,Philip Konopa,Snehal Nariya,Julia N. Stoddard,Kim G. Wong,Hong Zhao,Wenjie Deng,Brandon S. Maust,Meera Bose,Shana Howell,Adam Bates,Michelle Lazzaro,Annemarie O'Sullivan,Esther Lei,Andrea Bradfield,Grace Ibitamuno,Vatcharain Assawadarachai,Robert J. O'Connell,Mark S. deSouza,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Merlin L. Robb,Jason S. McLellan,Ivelin S. Georgiev,Peter D. Kwong,Jonathan M. Carlson,Nelson L. Michael,William R. Schief,William R. Schief,Peter B. Gilbert,James I. Mullins,Jerome H. Kim +45 more
TL;DR: Genetic signatures of RV144 vaccination in V2 complement the finding of an association between high V1/V2-binding antibodies and reduced risk of HIV-1 acquisition, and provide evidence that vaccine-induced V2 responses plausibly had a role in the partial protection conferred by the RV144 regimen.
Journal ArticleDOI
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
Nicole L. Yates,Nicole L. Yates,Hua-Xin Liao,Hua-Xin Liao,Youyi Fong,Allan C. deCamp,Nathan Vandergrift,Nathan Vandergrift,William T. Williams,William T. Williams,S. Munir Alam,S. Munir Alam,Guido Ferrari,Guido Ferrari,Zhi Yong Yang,Kelly E. Seaton,Kelly E. Seaton,Phillip W. Berman,Michael D. Alpert,David T. Evans,Robert J. O'Connell,Donald P. Francis,Faruk Sinangil,Carter Lee,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Jaranit Kaewkungwal,Punnee Pitisuttithum,James Tartaglia,Abraham Pinter,Susan Zolla-Pazner,Peter B. Gilbert,Gary J. Nabel,Nelson L. Michael,Jerome H. Kim,David C. Montefiori,David C. Montefiori,Barton F. Haynes,Barton F. Haynes,Georgia D. Tomaras +39 more
TL;DR: HIV-1–specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine, and should be evaluated in future HIV-1 vaccine efficacy trials to further refine immune correlates of protection.
Journal ArticleDOI
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
Hua-Xin Liao,Mattia Bonsignori,S. Munir Alam,Jason S. McLellan,Georgia D. Tomaras,M. Anthony Moody,Daniel M. Kozink,Kwan Ki Hwang,Xi Chen,Chun Yen Tsao,Pinghuang Liu,Xiaozhi Lu,Robert Parks,David C. Montefiori,Guido Ferrari,Justin Pollara,Mangala Rao,Kristina K. Peachman,Sampa Santra,Norman L. Letvin,Nicos Karasavvas,Zhi-Yong Yang,Kaifan Dai,Marie Pancera,Jason Gorman,Kevin Wiehe,Nathan I. Nicely,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Jaranit Kaewkungwal,Punnee Pitisuttithum,James Tartaglia,Faruk Sinangil,Jerome H. Kim,Nelson L. Michael,Thomas B. Kepler,Peter D. Kwong,John R. Mascola,Gary J. Nabel,Abraham Pinter,Susan Zolla-Pazner,Susan Zolla-Pazner,Barton F. Haynes +42 more
TL;DR: Four V2 monoclonal antibodies from RV144 vaccinees are isolated that recognize residue 169, neutralize laboratory-adapted HIV-1, and mediate killing of field-isolate HIV- 1-infected CD4(+) T cells, providing vaccine designers with new options.